GlassScriptPhysician profile
Jacob Carson Sellers
NPI 1326696071
$11,722.92
in general payments reported to CMS, 2019-2025
40 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,696 · 2022: $3,468 · 2023: $3,128 · 2024: $1,186 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,382 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,382.10 |
| Education | $177.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,967.58 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,352.73 | 2021-2025 | Breztri, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,135.76 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $824.73 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.66 | 2021-2024 | Ofev, Stiolto Respimat |
| Insmed, INC. | $597.83 | 2021-2025 | Arikayce |
| Genzyme Corporation | $555.63 | 2021-2025 | |
| Axsome Therapeutics, INC. | $514.63 | 2022-2025 | Sunosi |
| United Therapeutics Corporation | $479.23 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Amgen INC. | $389.97 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $368.51 | 2021-2024 | Acthar |
| Mylan Specialty L.P. | $353.93 | 2021-2024 | Yupelri |
| Harmony Biosciences LLC | $266.14 | 2021-2025 | Wakix |
| Merck Sharp & Dohme LLC | $244.07 | 2021-2025 | Zerbaxa, Winrevair, Dificid |
| Jazz Pharmaceuticals INC. | $231.78 | 2021-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $218.78 | 2023-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $212.01 | 2025 | Lumryz |
| Electromed, INC. | $170.73 | 2022 | |
| Pulmonx Corporation | $152.78 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $119.92 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $115.94 | 2021-2025 | Glassia |
| Shionogi INC | $96.80 | 2022 | |
| Alexion Pharmaceuticals, INC. | $92.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $76.06 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $70.92 | 2023-2024 | Purified Cortrophin Gel |
| Inari Medical, INC. | $68.81 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Baxter Healthcare | $66.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $59.24 | 2021 | |
| Grifols USA, LLC | $43.71 | 2021-2024 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $33.93 | 2021 | |
| Idorsia Pharmaceuticals US INC | $33.15 | 2023 | Quviviq |
| Philips North America LLC | $21.38 | 2022 | |
| Lilly USA, LLC | $20.48 | 2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $20.33 | 2021 | |
| Viatris Specialty LLC | $17.71 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $15.28 | 2022 | |
| Ambu INC. | $13.88 | 2023 | |
| Fisher & Paykel Healthcare INC | $11.71 | 2021 | |
| Abbvie INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.